Showing 6331-6340 of 7027 results for "".
- One Quarter of Americans Misled by Online Info: Surveyhttps://practicaldermatology.com/news/one-quarter-of-americans-misled-by-online-info-survey/2458841/One in four Americans (24 percent) say they have been misled by information about an illness or medical symptom from an unverified online source, according to a new survey from Merck Manuals. That figure increases to 30 percent among parents with children under 18 and jumps to 43 percent among mi
- LEO Pharma Inc. Announces FDA Approval of Enstilar Foam for Plaque Psoriasishttps://practicaldermatology.com/news/leo-pharma-inc-announces-fda-approval-of-enstilar-foam-for-plaque-psoriasis/2458842/The FDA approved LEO Pharma Inc’s Enstilar for the topical treatment of plaque psoriasis in adults 18 years of age and older. Enstilar is a once-daily, alcohol free foam formulation in a pressurized spray can that allows application across large body areas of plaque psoriasis. In th
- RXi Pharmaceuticals Announces Positive Interim Results in Phase 2a Dermatology Program with RXI-109https://practicaldermatology.com/news/rxi-pharmaceuticals-announces-positive-interim-results-in-phase-2a-dermatology-program-with-rxi-109/2458844/RXi Pharmaceuticals Corporation shared results from a blinded panel and an Investigator review showing that incision sites treated with RXI-109 after scar revision surgery achieved better scores as compared to control incision sites in the same subjects, three months post scar revision surgery.</
- Study Demonstrates Duac Significantly Reduces Inflammatory Acne Lesionshttps://practicaldermatology.com/news/study-demonstrates-duac-significantly-reduces-inflammatory-acne-lesions/2458846/Stiefel shared the findings of a head-to-head German study demonstrating that, in patients with mild-to-moderate acne vulgaris, treatment with Duac™ 3% (benzoyl peroxide 3% + clindamycin 1%) led to numerically fewer inflammatory and non-inflammatory lesions from baseline compared to treatme
- FDA Accepts sNDA for Dalvancehttps://practicaldermatology.com/news/fda-accepts-snda-for-dalvance/2458849/The FDA accepted Allergan's supplemental New Drug Application (sNDA) to expand the label to include single-dose administration of DALVANCE® (dalbavancin) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults caused by design
- A Novel Dual-Wavelength, Nd:YAG, Picosecond-domain Laser Safely and Effectively Removes Multicolor Tattooshttps://practicaldermatology.com/news/a-novel-dual-wavelength-ndyag-picosecond-domain-laser-safely-and-effectively-removes-multicolor-tattoos/2458848/Research conducted by Eric F. Bernstein MD, MSc; Kevin T. Schomacker PhD; Lisa D. Basilavecchio RN; Jessica M. Plugis; and Jayant D. Bhawalkar PhD, published in the September 2015 issue of Lasers in Surgery and Medicine (LSM), evaluated 21 tattooed subjects between the ages of 19-55 who
- Novan Appoints Chief Financial Officer and Chief Commercial Officer to Leadership Teamhttps://practicaldermatology.com/news/novan-appoints-chief-financial-officer-and-chief-commercial-officer-to-leadership-team/2458851/Novan Therapeutics appointed two new executives from the dermatology industry to the company's leadership team. Richard Peterson has joined the company as Chief Financial Officer and Brian Johnson as Chief Commercial Officer. Mr. Peterson will be responsible for the company's financi
- Allergan Completes Acquisition of Kybella Maker Kytherahttps://practicaldermatology.com/news/allergan-completes-acquisition-of-kybella-maker-kythera/2458856/Allergan plc has successfully completed the acquisition of Kythera Biopharmaceuticals, Inc. Allergan acquired Kythera in an all-cash transaction valued at approximately $2.1 billion. The acquisition of Kythera adds Kybella® (deoxych
- Nivolumab Approved in Combination with Ipilimumabhttps://practicaldermatology.com/news/nivolumab-approved-in-combination-with-ipilimumab/2458859/The FDA has granted accelerated approval to nivolumab (Opdivo Injection, Bristol-Myers Squibb Company) in combination with ipilimumab for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma. The clinical trial that supported approval randomized (2:1) 142
- Novan's SB204 Demonstrates Positive Phase 2b Clinical Trial Results for the Treatment of Acne Vulgarishttps://practicaldermatology.com/news/novans-sb204-demonstrates-positive-phase-2b-clinical-trial-results-for-the-treatment-of-acne-vulgaris/2458863/Novan Therapeutics topical nitric oxide drug candidate SB204 for the treatment of acne vulgaris, demonstrated statistically significant reductions in the percent change of non-inflammatory (white heads and black heads) and